Strategies for Mitigating the Unpredictability of Fc-Mediated Functions in Antibody Development

Optimization of Fc function can lead to the development of safer and more efficacious therapeutic antibody products, but analyses of Fc function may be underexploited in the antibody design process. We introduce a high-throughput platform for antigen-specific testing of Fc effector activities, empowering enhanced hit-to-lead screening in early stages of antibody development for the treatment of cancer, autoimmunity, neurodegeneration, and infectious diseases.
Speaker: Lenny Moise, PhD, VP Research, SeromYx Systems
Dr. Lenny Moise, VP Research, oversees the scientific development of the SeromYx Systems Serology platform, driving clinical research and drug discovery in infectious disease, immuno-oncology, autoimmunity, and neurology. Previously, as Director of Vaccine Research at EpiVax, he harnessed immunoinformatics to design innovative vaccines leveraging T cell immunity for viral and bacterial infectious diseases and cancer. Over that time, he studied T cell responses to vaccines and developed immunoinformatic tools as a faculty member at the Institute for Immunology and Informatics (University of Rhode Island) and the Center for Vaccines and Immunology (University of Georgia). Lenny trained in structure-function analysis of snake toxin-ion channel interactions using structural, biochemical, and electrophysiological methods and holds a Bachelor of Science and a doctorate from Brown University.